Recent Analysts’ Ratings Changes for Healthpeak Properties (DOC)

A number of research firms have changed their ratings and price targets for Healthpeak Properties (NYSE: DOC):

• 6/15/2026 – Healthpeak Properties had its price target raised by BMO Capital Markets from $20.00 to $24.00. They now have an “outperform” rating on the stock.
• 6/11/2026 – Healthpeak Properties had its “equal weight” rating reaffirmed by Morgan Stanley. They now have a $22.00 price target on the stock, up from $20.00.
• 6/1/2026 – Healthpeak Properties had its price target raised by Wells Fargo & Company from $18.00 to $20.00. They now have an “equal weight” rating on the stock.
• 5/27/2026 – Healthpeak Properties had its price target raised by Scotiabank from $19.00 to $21.00. They now have a “sector perform” rating on the stock.
• 5/22/2026 – Healthpeak Properties had its price target raised by Morgan Stanley from $18.00 to $20.00. They now have an “overweight” rating on the stock.
• 5/14/2026 – Healthpeak Properties had its price target raised by Royal Bank Of Canada from $20.00 to $21.00. They now have an “outperform” rating on the stock.
• 5/13/2026 – Healthpeak Properties had its price target raised by UBS Group AG from $17.00 to $19.00. They now have a “neutral” rating on the stock.
• 5/13/2026 – Healthpeak Properties had its price target raised by Robert W. Baird from $19.00 to $21.00. They now have an “outperform” rating on the stock.
• 5/12/2026 – Healthpeak Properties had its price target raised by Citigroup Inc. from $17.50 to $20.00. They now have a “neutral” rating on the stock.
• 5/11/2026 – Healthpeak Properties was downgraded by Evercore Inc from “outperform” to “in-line”. They now have a $21.00 price target on the stock.
• 5/10/2026 – Healthpeak Properties was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/8/2026 – Healthpeak Properties was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 5/2/2026 – Healthpeak Properties was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/28/2026 – Healthpeak Properties had its price target lowered by Morgan Stanley from $21.00 to $18.00. They now have an “overweight” rating on the stock.
• 4/24/2026 – Healthpeak Properties had its “hold (c-)” rating reaffirmed by Weiss Ratings.
• 4/23/2026 – Healthpeak Properties was upgraded by Scotiabank to “hold”.
• 4/20/2026 – Healthpeak Properties is now covered by UBS Group AG. They set a “neutral” rating and a $17.00 price target on the stock.

Healthpeak Properties Dividend Announcement

The business also recently disclosed a monthly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 15th will be issued a $0.1017 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a c) annualized dividend and a yield of 6.0%. Healthpeak Properties’s payout ratio is currently 381.25%.

Insiders Place Their Bets

In other Healthpeak Properties news, insider Scott R. Bohn sold 10,989 shares of Healthpeak Properties stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total value of $213,736.05. Following the completion of the transaction, the insider directly owned 7,636 shares of the company’s stock, valued at $148,520.20. The trade was a 59.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.23% of the stock is owned by corporate insiders.

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.